Search results | ranbaxy

Reports

Partnering Agreements with Ranbaxy

The Partnering Agreements with Ranbaxy report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

Insights

Ranbaxy

Ranbaxy Laboratories is a top pharmaceutical company based in Haryana, India

Ranbaxy: One of the world’s fastest growing pharmaceuticals companies

Ranbaxy is a research based pharmaceutical company with a strong focus on developing generics.

Ranbaxy: Partnering activity 2009-2014

Ranbaxy, a research based big pharma company with its headquarters in India, has announced 14 partnering / licensing deals since 2009, with 5 deals in 2010 alone.

Ranbaxy retains exclusivity for Diovan

Indian pharma major  Ranbaxy is likely to announce a tie-up with a multinational company for sourcing active pharmaceutical ingredient (API) for its blood pressure drug- Diovan.

Ranbaxy Laboratories also looking to sell its vaccine business

Drug maker Ranbaxy Laboratories is likely to sell off Biovel, a Bangalore-based vaccine manufacturing company which it had acquired in 2010.

Ranbaxy: Company Profile

Ranbaxy Laboratories, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Life Science M&A Deal Trends in Q2, 2014

By Steve Poile                                     With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.

A review of the Top 50 Pharma companies of 2014

The 2014 top 50 Pharma company list is out, with an interesting number of movers and shakers By Alamelu Elango

Sun Pharmaceutical: M&A activity 2009-2014

Sun Pharmaceutical has announced 6 M&A deals since 2009.

Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan

Events

Sorry, your search returned no results.


Deals

Merger completed between Ranbaxy and Sunpharma

Mumbai, India: March 25, 2015 – Sun Pharmaceutical Industries Ltd., begins the integration of Ranbaxy’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.

Sun Pharma and Ranbaxy engage in M&A transaction

Sun Pharmaceutical agreed to m&a transaction to buy competitor Ranbaxy Laboratories for $3.2 billion from Japan’s Daiichi Sankyo, which paid 61 percent more for the company five years ago.

Daiichi Sankyo to launch products in Mexico through Ranbaxy Laboratories

Additionally, the companies have agreed to promote prasugrel, an anti-platelet co-developed by Daiichi Sankyo and Eli Lilly and Company, in Mexico. Prasugrel will be co-promoted by Lilly’s affiliate in Mexico.

Daiichi to bid for up to 20 percent of Ranbaxy’s Zenotech

Daiichi Sankyo acquired a 63.9 percent stake in Ranbaxy Laboratories last year.

KKR invest $200 million in Gland Pharma

U.S. buyout firm KKR & Co LP  has agreed to invest about $200 million in Indian drugmaker Gland Pharma Ltd, marking the largest private equity investment in the local pharmaceutical sector amid growing demand for generic drugs in overseas markets.

Gilead Sciences collaborates with Indian pharma partners for antiretroviral therapy

Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into a pharma partners agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

Teva looks set for a new round of M&A deals

Teva Pharmaceutical Industries aims to reduce its reliance on its key multiple sclerosis drug and expand in markets beyond the United States after a rise in profits due partly to growing sales of Copaxone.